DGAP-News: STRATEC Biomedical AG / Key word(s): Contract/Alliance
Quanterix and STRATEC announce strategic partnership
16.08.2011 / 07:15
---------------------------------------------------------------------
Quanterix and STRATEC announce strategic partnership
STRATEC to develop and manufacture instrument to automate Quanterix's
Single Molecule Array Technology for the life sciences and in vitro
diagnostics markets
CAMBRIDGE, MA, USA and BIRKENFELD, GERMANY, August 16, 2011
Quanterix Corporation, a company enabling a new generation of molecular
diagnostic tests based on its revolutionary Single Molecule Array
(SiMoA(TM)) technology, and STRATEC Biomedical AG (Frankfurt: SBS; Prime
Standard, TecDAX), a worldwide leader in the development and manufacture of
automated analyzer systems, today announced an agreement to co-develop and
manufacture a fully-automated instrument for Quanterix's SiMoA technology
for use in both the life sciences and in vitro diagnostics (IVD) markets.
Quanterix expects to launch a life sciences instrument in 2013, followed by
the commercialization of an IVD platform in 2014.
As part of the agreement, Quanterix will receive access to STRATEC's
platform technology, which will be customized to both optimize and automate
the advanced applications of Quanterix's SiMoA technology. STRATEC will
receive payments, as well as a minority stake of approximately 7% in the
share capital of Quanterix, upon the achievement of technological
milestones. After completion of the development phase, STRATEC will
manufacture and supply the system and Quanterix has committed to order an
agreed minimum volume of systems.
'We are excited to collaborate with STRATEC, a world-class company with an
international presence in the biotech and diagnostics marketplace,' said
Martin Madaus, Ph.D., Quanterix Executive Chairman. 'STRATEC's unparalleled
expertise in developing automation solutions will enable Quanterix to bring
our single molecule detection technology to the market in a format that
will address the needs of both clinical labs as well as individual research
scientists. This new Quanterix detection platform will enable direct and
non-amplified detection of pathogens at levels of sensitivity that could
previously only be achieved with amplification methods. The system will
allow for completely new clinical insights from the measurement of protein
biomarkers that were difficult to measure due to sensitivity and precision
limitations of conventional technologies.'
David Walt, Ph.D., Scientific founder of Quanterix added 'The introduction
of a fully-automated system will represent the next phase of development
for Quanterix's SiMoA technology. With STRATEC's expertise in the design
and manufacture of this instrument platform, Quanterix can focus on
developing content for the system and pursuing applications with the
largest impact on advancing molecular diagnostics.'
'We are very pleased to work with Quanterix on the development of an
instrument that facilitates automation of this potentially game-changing
technology,' said Marcus Wolfinger, CEO and Chairman of the Board of
Management, STRATEC Biomedical AG. 'The quality and potential for Quanterix
and its technology is evidenced by the background and accomplishments of
the Quanterix team, and we look forward to providing a platform solution
that will allow Quanterix to expand the utility of SiMoA in both the life
sciences research and IVD markets.'
About Quanterix
Quanterix Corporation is developing its proprietary Single Molecule Array
(SiMoA(TM)) technology for the in vitro diagnostics and life science
research markets. The digital nature of SiMoA yields unprecedented assay
performance, stemming from a 1,000-fold improvement in sensitivity compared
with today's analog only technology. SiMoA will enable researchers in life
science to validate novel, low abundance biomolecules from a single droplet
of blood, leading to greater insight into disease detection, diagnosis,
therapy selection and disease monitoring. Automated systems based on SiMoA
are being designed to provide diagnostic test information to healthcare
practitioners faster, with greater reliability, unprecedented range and
increased cost effectiveness. Founded in 2007, the privately held
Cambridge, Massachusetts-based company is backed by leading life science
investors including ARCH Venture Partners, Bain Capital Ventures, and
Flagship Ventures. For additional information, please visit
www.quanterix.com.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, to laboratories, blood banks and
research institutes around the world. The company develops its products on
the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical AG and of subsidiaries and second-tier subsidiaries in Germany,
the USA, the UK, Switzerland and Romania.
Media contacts:
Quanterix
David Hanlon
Phone: +1 617-301-9430
dhanlon@quanterix.com
www.quanterix.com
STRATEC Biomedical AG
Andreas Kuenzel
Phone: +49 7082 7916185
ir@stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
16.08.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
135761 16.08.2011
DGAP-News: Quanterix and STRATEC announce strategic partnership
| Source: EQS Group AG